Want to join the conversation?
$DHR agreed to buy $CPHD. $DHR estimates $CPHD acquisition will be moderately dilutive to GAAP EPS and about $0.05 accretive to non-GAAP EPS in the first full year post acquisition. In the fifth full year post acquisition, the company expects acquisition to be about $0.30 accretive to non-GAAP EPS.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.